Related coverage linked through entity extraction aliases.
Aug 20, 2026
The FDA granted breakthrough therapy designation to subcutaneous amivantamab for recurrent or metastatic HPV-unrelated HNSCC after progression on platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. The decision was supported by OrigAMI-4 cohort 1 data showing a 45% ORR and 76% clinical benefit rate.
Aug 17, 2026
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
Jun 11, 2026
A review of ClinicalTrials.gov registrations found few late-stage trials with robust sleep outcome measures in elderly Parkinson's disease patients. The analysis in BMC Geriatrics highlights outcome measure heterogeneity, underrepresentation of older adults, and short study durations as key gaps.
May 14, 2026
The FDA approved oral decitabine and cedazuridine tablets plus venetoclax for newly diagnosed AML in patients 75 and older or those ineligible for intensive induction chemotherapy. The approval was supported by phase 1/2 ASTX727-07 data showing a 41.6% complete response rate.
Mar 13, 2026
Real-world data from over 300 large B-cell lymphoma patients treated with axicabtagene ciloleucel show response rates and survival outcomes remarkably similar to pivotal trial results, with 86% overall response rate and 74% one-year survival.
Feb 28, 2026
Three interconnected life sciences infrastructure markets are experiencing significant growth driven by precision medicine adoption, increasing clinical trial activity, and advances in genomic diagnostics through 2035.
Feb 26, 2026
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Feb 23, 2026
Two clinical trials demonstrate efficacy of talimogene laherparepvec (T-VEC) oncolytic virus therapy in HER2-negative breast cancer and nonmelanoma skin cancers, with favorable safety profiles and durable responses in subset of patients.
